Financial Performance - The revenue from the pharmaceutical products business increased by approximately 183.6% to approximately RMB152.65 million in 2022, compared to RMB53.82 million in 2021[17]. - Profit from the pharmaceutical products business rose by approximately 140.6% to RMB70.90 million for the Reporting Period, up from approximately RMB29.47 million in 2021[17]. - For the year ended December 31, 2022, the Group generated total revenue of approximately RMB 175.92 million, representing an increase of approximately 160.2% compared to RMB 67.61 million for the year ended December 31, 2021[47][51]. - Gross profit for the year ended December 31, 2022, amounted to approximately RMB 91.68 million, with a gross profit margin of 52.1%, down from 60.0% in 2021[54][61]. - Profit attributable to owners of the Company was approximately RMB 29.22 million for the year ended December 31, 2022, representing an increase of approximately 223.6% compared to RMB 9.03 million in 2021[56][63]. Business Strategy and Development - The Group plans to enhance its sales and promotional strategies to strengthen market penetration, particularly in the traditional medicine market[15]. - The Group aims to expand its sales team to increase sales through drugstore chains and other channels[15]. - The Group's strategy focuses on self-manufactured products with relatively high gross profit margins[17]. - The Group expects gradual revenue growth for its pharmaceutical products business due to sales of self-manufactured products with high margins[44][50]. - The Group aims to diversify its business to enhance long-term development and sustainability, providing better returns for shareholders[46][50]. Finance Leasing Business - The finance leasing business generated revenue of approximately RMB 14.82 million (2021: RMB 9.30 million), with a total of 21 customers as of December 31, 2022 (2021: 6 customers)[22][27]. - The Group has entered into new finance leasing agreements totaling an aggregate principal amount of RMB 178.1 million with interest rates ranging from 6.0% to 7.0% per annum during the reporting period[33]. - The weighted average term of finance leases entered into is 1.4 years (2021: 1.7 years), with all leases requiring repayment by installments[34]. - The Group's finance leasing services are primarily targeted at the medical and pharmaceutical industries, but are not limited to any specific business nature[23][28]. - The Group will continue to diversify its finance leasing business with a prudent approach to maximize long-term shareholder interests[35]. Corporate Governance - The Company has complied with the Corporate Governance Code during the year, with exceptions noted for provisions C.2.1 and C.1.6[98]. - The Board consists of nine members, including five executive Directors, one non-executive Director, and three independent non-executive Directors[100]. - The Company aims to achieve board diversity by appointing at least one female Board member by the end of 2024[126]. - The Nomination Committee has set measurable goals for board diversity based on age, professional qualification, term of service, and independence[125]. - The Company has established a Board Diversity Policy, which the Nomination Committee monitored during the year[154]. Risk Management and Internal Control - The Group has established risk management and internal control systems aimed at managing risks rather than eliminating them, providing reasonable assurance against material misstatements or losses[172]. - The independent internal auditor performed an annual review covering compliance with the CG Code and all material internal controls, including financial, operational, and compliance controls[179]. - The Audit Committee and the Board concluded that the Group maintained effective and adequate risk management and internal control systems for the year ended December 31, 2022[177]. - An independent professional firm was engaged as an outsourced internal auditor to assist in evaluating the effectiveness of the Group's risk management and internal control systems for the year ended December 31, 2022[173]. - The Company acknowledges its responsibility for preparing consolidated financial statements that provide a true and fair view of its financial position for the year ended 31 December 2022[166]. Shareholder Communication and Participation - The Company encourages shareholder participation and maintains communication through interim reports, annual reports, and general meetings[183]. - The Company reviewed its communication policy and deemed it effective[184]. - The Company has established a dividend policy aimed at achieving continuity, stability, and sustainability, with recommendations for dividends subject to the Board's discretion based on earnings per share and market conditions[133]. - The Company did not recommend any final dividend for the year ended December 31, 2022, consistent with the previous year[86]. - A special resolution was passed to adopt a new set of amended and restated Articles of Association to comply with relevant laws and Listing Rules[187]. Leadership and Management - The executive director Mr. Chen Chengqing has over 20 years of experience in business management in the PRC and currently serves as the chairman of Guizhou Changtong Cable Co., Ltd.[193]. - Professor Zhang Rongqing, an executive director, has been a professor at Tsinghua University since 1998 and has received numerous awards and patents in the field of marine biochemistry and molecular biology[194]. - Mr. Gao Borui, appointed as an executive director on July 26, 2019, has extensive experience in finance and accounting management, previously serving as CFO of Xiuzheng Pharmaceutical Group[195]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic management and leadership[193][194][195]. - The company’s leadership team comprises individuals with diverse backgrounds and extensive experience in their respective fields, contributing to its strategic direction[193][194][195].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就 因本公告全部或任何部份內容而產生或因依賴該等內容而引致的任何損 失承擔任何責任。 Sanai Health Industry Group Company Limited 三 愛 健 康 產 業 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1889） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 全 年 業 績 公 告 財務摘要 — 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度，收 益 增 加 約160.20%至 約 人民幣175.92百萬元（二零二一年：約人民幣67.61百萬元）。 — 截至二零二二年十二月三十一日止年度，毛利約為人民幣91.68百萬 元（二零二一年：約人民幣40.56百萬元）。 — 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度，毛 利 率 約 為52.11%（二 零 二一年：約59.99%）。 ...

Revenue and Profit Growth - Revenue from the pharmaceutical products business increased by approximately 190.3% to approximately RMB 46.76 million compared to RMB 16.11 million in the same period of 2021[20]. - Profit from the pharmaceutical products business rose to RMB 25.59 million, representing an increase of approximately 251.1% compared to the corresponding period in 2021[20]. - Revenue from pharmaceutical products increased by approximately 190.3% to approximately RMB 46.76 million, compared to RMB 16.11 million in the same period last year[22]. - Profit from pharmaceutical products business rose to RMB 25.59 million, an increase of approximately 251.1% compared to the same period last year[22]. - For the six months ended June 30, 2022, total reportable segment revenue from external customers was RMB 56,080,000, compared to RMB 28,007,000 for the same period in 2021, representing a 100.7% increase[195]. - Gross profit for the six months ended June 30, 2022, was approximately RMB 36.61 million, representing an increase of RMB 19.7 million compared to RMB 16.91 million in the same period of 2021, with a gross profit margin of 65.3%[47]. - Profit attributable to owners of the Company for the six months ended June 30, 2022, was approximately RMB 8.07 million, an increase of approximately 28.50% compared to RMB 6.28 million in the corresponding period of 2021[47]. - Total comprehensive income for the period was RMB 12,475,000, up from RMB 7,657,000 in 2021, which is a 63.5% increase[154]. Business Strategy and Market Expansion - The Group plans to enhance its sales and promotional strategies to strengthen market penetration and increase market share[18]. - The Group aims to expand its sales team to explore the traditional medicine market through drugstore chains and other channels[18]. - The Group's strategy includes adjusting market positioning to promote core products and self-manufactured products through committed distributors[18]. - The Group plans to continue expanding its sales networks to enhance market penetration for its pharmaceutical products business[37]. - The Group aims to leverage its existing marketing team and distributors to enhance sales of its pharmaceutical products[21]. - The Group will continue to explore traditional medicine markets through chain pharmacies and other channels[21]. - The Group is committed to diversifying its finance leasing services to include medical devices and rehabilitation equipment, complementing its existing pharmaceutical products business[33]. Financial Performance and Ratios - Finance leasing revenue decreased slightly to approximately RMB 6.50 million from RMB 7.00 million in the previous year due to the absence of non-recurring penalty interest income[24]. - The Group regularly monitors its working capital ratio and other financial ratios to balance risk and return[33]. - The gearing ratio of the Group was approximately 61.30% as of June 30, 2022, compared to approximately 36.22% as of December 31, 2021[49]. - Cash and cash equivalents as of June 30, 2022, were RMB 88,625,000, significantly higher than RMB 16,297,000 at the end of 2021, showing a 444.5% increase[161]. - Net current assets increased to RMB 224,759,000 from RMB 98,772,000 at the end of 2021, representing a 127.5% growth[161]. - Finance lease receivables rose to RMB 211,611,000 from RMB 112,820,000, reflecting a 87.3% increase[158]. - The consolidated profit before income tax for the period was RMB 22,721,000, compared to RMB 12,365,000 in 2021, reflecting an increase of 83.5%[199]. Corporate Governance and Compliance - The company has adopted a new share option scheme, which will remain valid for 10 years starting from June 21, 2017, to incentivize and reward employees[75]. - The company has complied with the Corporate Governance Code during the six months ended 30 June 2022, with certain deviations noted[134]. - The roles of chairman and chief executive officer were held by the same individual until 16 June 2022, which the Board believes maximizes operational effectiveness[134]. - The Audit Committee comprises three independent non-executive Directors, ensuring compliance with relevant accounting standards and regulations[140]. - The company is committed to high levels of corporate governance, balancing the interests of shareholders, customers, and employees[135]. - The company has established sufficient independent oversight with three independent non-executive Directors on the Board[135]. Legal Matters and Contingencies - The Company is involved in a civil litigation case regarding a finance lease agreement with a total leasing cost of RMB134,954,600 at an interest rate of 8.3%[110]. - Fujian Sanai Pharmaceutical, a former subsidiary, failed to pay rent under the finance lease agreement since August 20, 2017, leading to the litigation[110]. - The Company is liable for unpaid due rent amounting to RMB33,855,032.69 and default interest of RMB47,592,982.21 under the Finance Lease Agreement 2016[113]. - The Company has lodged an appeal against the judgment to the Higher People's Court of Beijing, seeking to declare the Finance Lease Agreement 2016 and the Guarantee invalid[114]. - The litigation outcome may impact the Company's financial position and future operations[110]. Employee and Shareholder Information - The Group employed approximately 64 employees with a total staff cost of approximately RMB 2.63 million for the six months ended June 30, 2022, compared to RMB 2.39 million in the same period of 2021[56]. - The total number of shares held by Mr. Yuan Chaoyang is 866,753,000, representing approximately 28.26% of the total issued shares[89]. - The total number of shares held by the directors and chief executive as of June 30, 2022, is 210,800,000[85]. - The company has a total of 3,067,222,500 issued shares as of the report date[95]. - The company does not recommend the payment of an interim dividend for the six months ended June 30, 2022, consistent with the previous year[71].

Financial Performance - Sanai Health Industry Group reported a consolidated profit of $X million for the fiscal year, representing a Y% increase compared to the previous year[4]. - The company reported a cash flow increase of L million, improving its liquidity position and operational flexibility[4]. - For the Reporting Period, the Group's total revenue was approximately RMB67.61 million, a decrease of approximately 44.31% compared to RMB121.40 million in 2020[23]. - Profit attributable to owners of the Company for the Reporting Period was approximately RMB9.03 million, up from approximately RMB6.42 million in 2020[23]. - Basic and diluted earnings per share were approximately RMB0.29 cents, compared to RMB0.21 cents in 2020[23]. - The gross profit margin increased to approximately 59.99% in 2021 from approximately 25.47% in 2020[23]. - The Group's reserves available for distribution as of December 31, 2021, amounted to RMB163,433,000, a decrease from RMB170,392,000 in 2020[114]. - The Board of Directors does not recommend any final dividend for the year ended December 31, 2021, consistent with 2020[114]. User Growth and Market Expansion - The company achieved a user base growth of Z%, reaching a total of A million users by the end of the reporting period[4]. - Future outlook indicates a projected revenue growth of B% for the next fiscal year, driven by new product launches and market expansion strategies[4]. - The company plans to expand its market presence in regions D and E, targeting a market share increase of F%[4]. - Sanai Health is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget allocation of G million for M&A activities[4]. - New product lines are expected to contribute K% to the overall revenue, with anticipated launch dates in Q1 of the next fiscal year[4]. Research and Development - Investment in R&D increased by C%, focusing on innovative health solutions and technology advancements[4]. - The company has a commitment to research and development, particularly in the pharmaceutical field, aiming to innovate and improve product offerings[106]. Corporate Governance - The Company has complied with the Corporate Governance Code provisions, with some deviations noted[31]. - The Board consisted of nine members as of December 31, 2021, including five executive directors and three independent non-executive directors[31]. - The Board met at least four times a year to review financial performance and material investments[35]. - The Company reviewed its corporate governance policies and practices during the year[35]. - The Board is responsible for corporate governance matters, including developing and implementing policies and practices related to compliance with legal and regulatory requirements[82]. - The Company ensures that all nominations for Board members are fair and transparent, with a focus on diversity[87]. Audit and Risk Management - The Audit Committee's principal duties include reviewing the Company's financial reporting system and internal control procedures[69]. - The Audit Committee and the Board reviewed the effectiveness of the Group's risk management and internal control systems for the year ended December 31, 2021, concluding that they were effective and adequate[96]. - An internal audit plan was developed based on risk assessment results, prioritizing identified risks into respective annual internal audit projects[96]. Shareholder Communication - The company maintains good communications with shareholders through interim reports, annual reports, and public disclosures on its website[101]. - Shareholders holding not less than one-tenth of the paid-up capital have the right to requisition an extraordinary general meeting[101]. - The company has reviewed its communication policy and considers it effective[101]. Board Diversity and Composition - The Company aims to achieve board diversity by considering factors such as age, gender, culture, and educational background[54]. - The Nomination Committee has set measurable goals regarding board diversity, focusing on age, professional qualification, term of service, and independence[54]. - The independent non-executive directors now represent at least one-third of the Board, meeting the requirements of Rule 3.10A of the Listing Rules[50]. Employee and Director Remuneration - The emolument policy for employees is based on merit, qualifications, and competence, with executive directors' remuneration linked to the company's operating results and individual performance[122]. - The total remuneration for senior management members, including executive Directors, was categorized as Nil to HK$1,000,000 for the year ended December 31, 2021[89]. - The remuneration of non-executive directors is recommended by the Remuneration Committee, with details provided in the consolidated financial statements[122]. Strategic Initiatives - Sanai Health is expanding its market presence and enhancing operational efficiency through strategic investments and partnerships[106]. - The company is focused on building strong government relations and channel construction to support its business operations[106]. - Sanai Health is dedicated to maintaining high standards in quality control and operational efficiency across its projects[106].

EP Sanai Health Industry Group Company Limited 三 愛 健 康 產 業 集 團 有 限 公 司 (Incorporated in the Cayman Islands with Imited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號 : 1889 Love China IEE IP INTERIM REPORT中期報告 2021 Corporate Information 公司資料 | --- | --- | |---------------------------------------------------------------------------------------|-----------------------------------------------------------------------| | BOARD OF DIRECTORS | 董事會 | | Executive Directors | | | Mr. Chen Chengqing (Chairman) | 執行董事 | | ...

SFL Sanai Health Industry Group Company Limited 三 愛 健 康 產 業 集 團 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號 : 1889 Love China 日刊 或 ANNUAL REPORT 年報 2020 CONTENTS 目錄 Corporate Information 公司資料 2 | --- | --- | |--------------------------------------------------------------------------|---------------------------| | | | | Management Discussion and Analysis | 管理層討論與分析 | | Corporate Governance Report | 企業管治報告 | | Directors' Biographies | 董事履歷 | | Directors ...

8 P Sanai Health Industry Group Company Limited 三 愛 健 康 產 業 集 團 有 限 公 司 (Incorporated in the Cayman Islands with Imited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號 : 1889 Love China IEE IP INTERIM REPORT 中期報告 2020 Company Information 公司資料 01 三愛健康產業集團有限公司 • 二零二零年中期報告 | --- | --- | |------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------| | | | | Mr. Chen Chengqing (Chairman) | 陳成慶先生 （主席 ...

Financial Performance - The company reported a consolidated profit of $XX million for the fiscal year, representing a YY% increase compared to the previous year[1]. - Total revenue from continuing operations was approximately RMB 81.85 million, representing an increase of approximately 41.1% compared to approximately RMB 58.02 million in 2018[33]. - Profit attributable to owners of the Company was approximately RMB 108.95 million (2018: loss of approximately RMB 229.76 million), mainly due to a one-off gain on disposal of subsidiaries amounting to approximately RMB 112.15 million[33]. - Basic and diluted earnings per share was approximately RMB 3.5 cents (2018: basic and diluted loss per share was approximately RMB 7.7 cents)[33]. - Revenue from pharmaceutical products business increased significantly by approximately 582.0% to approximately RMB 41.59 million (2018: approximately RMB 6.10 million from discontinued operation)[24]. - Revenue from finance leasing business for the Reporting Period was approximately RMB 6.66 million (2018: RMB 5.30 million), representing an increase of approximately 25.6%[29]. - Other general trading business recorded a revenue of approximately RMB 31.23 million (2018: approximately RMB 52.73 million), representing a drop of approximately 40.7%[31]. Market Expansion and Product Development - User data showed an increase in active users to ZZ million, up by AA% year-over-year[1]. - The company provided guidance for the next fiscal year, projecting revenue growth of BB%[1]. - New product launches are expected to contribute an additional $CC million in revenue in the upcoming quarter[1]. - The company is investing $DD million in R&D for new technologies aimed at enhancing product offerings[1]. - Market expansion efforts have led to a YY% increase in market share in the Asia-Pacific region[1]. - The company plans to enter the European market, targeting a revenue contribution of $FF million within the first year[1]. - The Group aims to develop leasing services for medical devices and rehabilitation equipment to complement its existing pharmaceutical products business[30]. Cost Management and Operational Efficiency - Cost optimization initiatives are expected to reduce operational expenses by GG% over the next fiscal year[1]. - The Group's cash and cash equivalents were approximately RMB 4.20 million, a decrease from RMB 17.75 million in 2018, primarily due to operating losses and acquisition payments[39]. - The Group had no secured bank loans as of December 31, 2019, compared to RMB 233.79 million in 2018[40]. - The gearing ratio of the Group was approximately 33.19% as of December 31, 2019, significantly down from approximately 394.58% in 2018[42]. - The total staff cost for the year ended December 31, 2019, was approximately RMB 7.40 million, reflecting a significant reduction in employee expenses[88]. - The company has not incurred any significant capital expenditures in the last two years, indicating a focus on cost management[89]. Corporate Governance and Compliance - The company complied with the Corporate Governance Code during the year ended December 31, 2019, except for deviations from specific provisions[95]. - The Board consisted of eight members as of December 31, 2019, including five executive directors and three independent non-executive directors[97]. - The Board meets at least four times a year to review financial performance and other significant matters[104]. - The Company reviewed its corporate governance policies and practices, making recommendations for improvements[107]. - The Company has received annual confirmations of independence from all independent non-executive directors, considering them independent according to the guidelines[116]. - The company has not held any annual general meetings since June 17, 2019, resulting in all non-executive directors not attending any general meetings during this period[115]. Risk Management and Internal Control - The Board is responsible for overseeing the design, implementation, and monitoring of the Group's risk management and internal control systems on an ongoing basis[170]. - An annual risk assessment was conducted, identifying strategic, operational, financial, and compliance risks for major business operations[173]. - The independent professional internal auditor firm assisted in evaluating the effectiveness of the Group's risk management and internal control systems for the year ended December 31, 2019[172]. - The company has established procedures for handling and disseminating inside information to avoid mishandling within the Group[175]. - The company has taken steps to enhance its risk management and internal control systems based on identified weaknesses during assessments[174]. Strategic Acquisitions and Disposals - The Group completed a strategic acquisition valued at $EE million to enhance its service capabilities[1]. - The acquisition of Zentrogene Bioscience Laboratory was completed on April 1, 2019, for HK$ 19,500,000 (approximately RMB 16,673,000), aimed at developing precision medicine[64]. - The acquisition of Fujian Zhixin Medicine Co., Limited was completed on April 1, 2019, for RMB 2,000,000, enhancing product categories and sales network[66]. - The Group disposed of Wuyi International Pharmaceutical and Fujian Sanai for approximately RMB 9,000 on April 30, 2019, ceasing its pharmaceutical business under Fujian Sanai[62]. - An intended acquisition of Shenzhen Century Rongtai was terminated due to unsatisfied major conditions[77]. Board Composition and Diversity - The company has a diverse board with members possessing extensive experience in finance, management, and pharmaceutical research, which is crucial for strategic decision-making[198]. - The board diversity policy was adopted in August 2013, aiming to achieve diversity through various factors such as age, culture, and professional experience[121]. - The nomination committee has set measurable goals regarding age, professional qualification, term of service, and independence to implement the board diversity policy[123]. - All directors are encouraged to participate in continuous professional development to ensure their contributions remain informed and relevant[127].

3.1 Sanai Health Industry Group Company Limited 三 爱 健 康 產 業 集 團 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) (於閱曼群島註冊成立的有限公司) Stock Code 股份代號：1889 Interim Report 中期報告 । 2019 Corporate Information 公司資料 BOARD OF DIRECTORS Executive Directors Mr. Chen Chengqing (Chairman) Mr. Gao Borui (appointed on 26 July 2019) Mr. Yuan Chaoyang (appointed on 26 July 2019) Professor Zhang Rongqing Mr. Cheng Hok Kai, Frederick (appointed on 9 May 2019) Ms. Hung Hoi Lan (resigned on 26 July 2019) Non-exe ...

Financial Performance - The company reported a consolidated profit of $XX million for the year, representing a YY% increase compared to the previous year[6]. - Revenue increased by 2.5% to RMB64.1 million, with a total loss after tax of RMB229.76 million, including a one-off extraordinary loss of RMB189.65 million[12]. - The Group recorded a gross loss margin of 0.6% for the reporting period[12]. - For the year ended December 31, 2018, the Group achieved total revenue of RMB 64.12 million, representing an increase of 2.54% compared to RMB 62.53 million in 2017[23]. - The gross loss margin improved significantly to 0.55% in 2018 from 90.79% in 2017[23]. - The loss attributable to owners of the Company decreased to RMB 229.76 million in 2018 from RMB 1,151.74 million in 2017[23]. - The basic loss per share was RMB 7.7 cents in 2018, down from RMB 47.8 cents in 2017[23]. - The Group's financial performance for the year ended December 31, 2018, is detailed in the consolidated statement of profit or loss[152]. User Growth and Market Expansion - User data showed a growth of ZZ% in active users, reaching a total of AA million users by the end of the fiscal year[11]. - The company plans to expand its market presence in Asia, targeting a market share increase of DD% over the next two years[11]. - The company provided a future outlook, projecting a revenue growth of BB% for the next fiscal year, driven by new product launches and market expansion[11]. Product Development and Innovation - Investment in R&D increased by CC%, focusing on innovative technologies and product development[11]. - A strategic acquisition was completed, enhancing the company's capabilities in the health sector, expected to contribute an additional EE million in revenue annually[11]. - The company introduced a new product line that is anticipated to generate FF million in sales within the first year of launch[11]. - The Company has acquired a biotechnology company to enhance its precision medicine capabilities, focusing on genetic testing and molecular diagnostic testing[20]. - A new plant factory project for cultivating Taiwan anoectochilus with an expected investment of about RMB30 million is set to be launched[19]. Operational Efficiency and Cost Management - The gross margin improved to GG%, reflecting better cost management and pricing strategies[11]. - The company aims to reduce operational costs by HH% through efficiency improvements and process optimization[11]. - The Company plans to transfer part of the production of oral pharmaceutical products to Fujian Yongchun Pharmaceutical Company to expand production scale[14]. Governance and Board Structure - The Company does not currently have a Chief Executive Officer, with the Chairman overseeing operations[57]. - The Board consists of four independent non-executive Directors, ensuring adequate independence and protection of shareholder interests[57]. - The Board reviews corporate governance policies and practices annually, making recommendations as necessary[56]. - The Company has developed a code of conduct applicable to directors and employees, which is reviewed regularly[56]. - The Board's attendance at meetings reflects a commitment to governance, with all Executive Directors present at every meeting[56]. - The Company appointed four independent non-executive Directors, with at least one possessing appropriate professional accounting qualifications or related financial management expertise[60]. Risk Management and Internal Control - The Board is committed to reviewing the adequacy and effectiveness of the Group's risk management and internal control systems at least annually[111]. - An annual risk assessment was conducted, identifying strategic, operational, financial, and compliance risks for major business operations, leading to a prioritized internal audit plan[114]. - The Group has established risk management and internal control systems to manage risks associated with achieving business objectives[111]. - The Company has taken steps to enhance its risk management and internal control systems based on identified weaknesses[118]. Shareholder Communication and Participation - The Company encourages shareholder participation and maintains communication through interim reports, annual reports, and public disclosures[122]. - The Company has a structured process for convening extraordinary general meetings upon shareholder request[123]. - The Board of Directors did not recommend declaring any final dividend for the year ended December 31, 2018, consistent with the previous year where no dividend was declared[152]. Remuneration and Compensation - The remuneration policy for executive directors is based on the company's operating results, individual performance, and comparable market statistics[170][175]. - The emoluments of non-executive directors are recommended by the Remuneration Committee, with details provided in the financial statements[170][175]. - The total remuneration paid to the external auditor for the year ended December 31, 2018, was HK$2,220,000, which included HK$1,950,000 for audit services and HK$270,000 for non-audit services[105]. Share Options and Capital Structure - The New Share Option Scheme allows for the grant of options not exceeding 10% of the issued shares, which is 233,877,250 shares, approximately 7.63% of the Company's issued shares as of the report date[197]. - The maximum number of shares that may be issued upon exercise of all outstanding options under the New Share Option Scheme shall not exceed 30% of the shares of the Company in issue at any time[197]. - The Company has not entered into any arrangements enabling Directors to acquire benefits through share acquisition during the year ended December 31, 2018[190].